Latest Regulatory Approvals News

NexGen Energy has entered the final phase of federal regulatory approval for its flagship Rook I uranium project, marking a pivotal step toward construction and production. This follows over a decade of environmental assessments and provincial approvals.

Brightstar Resources has received court approval to acquire Aurumin Limited, consolidating the Sandstone Gold Project and boosting its combined mineral resource to 2.4 million ounces. The acquisition positions Brightstar as a rising mid-tier gold producer in Western Australia.

Lloyds Banking Group is set to acquire London-based fintech Curve, aiming to enhance its mobile banking with advanced digital wallet features. The deal, expected to close in early 2026, marks a strategic push in Lloyds’ digital transformation journey.

The Takeovers Panel has declared unacceptable circumstances in the Mayne Pharma acquisition after Cosette Pharmaceuticals changed its intentions to close the Salisbury manufacturing site, raising concerns over market transparency and regulatory approval.

The Takeovers Panel has declared unacceptable circumstances in the Mayne Pharma acquisition, ordering Cosette Pharmaceuticals to comply with conditions preventing closure of the Salisbury manufacturing site. This ruling highlights concerns over market transparency and the integrity of the takeover process.

Bio-Gene Technology Limited updates on its development of two novel insecticides, Flavocide and Qcide, highlighting regulatory progress, commercial partnerships, and a strong market outlook across multiple sectors.

Bio-Gene Technology reports significant progress in developing its bio-insecticides Flavocide and Qcide, including new efficacy data and organic certification, positioning the company for growth amid rising global demand for safer pest control.

Bass Oil Limited reported a 32% jump in October sales revenue alongside a 4% rise in daily production, while advancing its strategic Vanessa gas field acquisition targeting first gas sales in the second half of 2026.

Dimerix Limited’s ACTION3 Phase 3 trial for DMX-200 in FSGS kidney disease has passed its seventh Independent Data Monitoring Committee review with no safety concerns, reinforcing the drug’s promising safety profile.

Horizon Oil Limited reported robust FY25 results, highlighted by a strategic acquisition of Thailand upstream assets and a 10-year permit extension at Maari, nearly doubling production and securing a strong outlook through 2030.

BCAL Diagnostics is preparing to launch its Avantect® pancreatic and ovarian cancer blood tests in Australia by January 2026, following key regulatory approvals and promising clinical data. The company also broadens the reach of its BREASTESTplus™ breast cancer test, targeting a larger segment of women with dense breast tissue.

Decidr AI Industries has announced a strategic acquisition of Delaware-based Sugarwork Inc., marking its official entry into the US market and enhancing its Agentic AI platform with advanced knowledge transfer capabilities.